Investor Relations
About Us:
InspireMD is a commercial-stage medical device company with proprietary and innovative embolic prevention systems (EPS)/thrombus management technologies and neurovascular devices that seek to overcome the harmful consequences of conventional stenting. InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events. InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures.
Highlights:
- Multi-billion dollar opportunity for MicroNet™ products for multiple vascular markets
- Current stents do not adequately address the risk of post-procedural embolization
- Consistent positive clinical trial results positioning CGuardTM as a potential standard-of-care in treating carotid artery disease
- Revenue growth driven by new commercialization strategy
- 84% sequential increase in sales of CGuard™ in Q1 ‘17
- Completed transition from exclusive European distributor (18 countries) to InspireMD managed regional distributor model
- Expanding CGuard™ users to a greater number of vascular surgeons, interventional cardiologists, and interventional radiologists
- Recent leadership changes focused on sales, marketing and high value pipeline development
- Strategic collaboration outreach expanding for multiple MicroNet™ product applications
- A broad portfolio of patent-protected assets
